LivaNova Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Explore the Complete Value Chain Behind the Preview
This LivaNova Value Chain Analysis gives you a clear view of how LivaNova creates value across support and primary activities in one practical framework. This page already shows a real preview of the actual analysis, so you can review the style and content before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
In FY2025, LivaNova PLC's firm infrastructure centered on quality systems, compliance, finance, and portfolio control, which is vital for a medtech group with 2 reporting segments: cardiovascular and neuromodulation. That setup helps coordinate product, regulatory, and capital decisions across multiple geographies while keeping FDA and EU MDR risk in check. For a business with about $1.3 billion in annual sales, tight governance is a direct driver of execution and margin control.
Human Resource Management
LivaNova's human resource management depends on engineers, clinical specialists, quality professionals, and commercial staff with medical device experience. Recruiting and keeping this talent supports product development, manufacturing discipline, and field execution across its two core therapy areas: cardiac surgery and neuromodulation. In FY2025, this skill base remained critical because regulated device work needs tight quality control, fast product cycles, and strong hospital-facing support.
Technology Development
LivaNova PLC's technology development centers on R&D for unmet needs in cardiovascular care and neuromodulation, including drug-resistant epilepsy and obstructive sleep apnea. In FY2025, that work supported product refinement, clinical evidence generation, and device innovation across heart-lung machines, oxygenators, and neuromodulation devices. This matters because innovation is the main source of differentiation in a market where regulatory proof and clinical outcomes drive adoption.
Procurement
LivaNova procurement is critical because it must source specialized components, medical-grade materials, electronics, and other regulated inputs with strict traceability. Strong sourcing control lowers supply risk, keeps quality stable, and helps protect manufacturing efficiency for complex devices where a single parts delay can disrupt output and patient supply.
LivaNova FY2025: Regulated Execution Behind $1.3B in Sales
In FY2025, LivaNova PLC's support activities were built around quality, compliance, finance, and portfolio control, which mattered for a $1.3 billion medtech group with 2 reporting segments. Its talent base of engineers, clinical specialists, quality staff, and commercial teams supported regulated execution across cardiovascular and neuromodulation. R&D and sourcing focused on product innovation and traceable inputs for heart-lung, oxygenation, and neuromodulation devices.
| Support activity | FY2025 signal |
|---|---|
| Firm infrastructure | 2 segments, $1.3B sales |
| Human resources | Specialized regulated talent |
| Technology development | R&D for epilepsy and sleep apnea |
| Procurement | Traceable medical-grade inputs |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
LivaNova PLC relies on a tightly controlled inbound supply chain for components, subassemblies, and sterile materials, because device quality starts at receipt. In 2025, that meant traceability and incoming inspection were not optional; they protected product reliability, compliance, and on-time production. For a medical device maker, even one weak lot can raise scrap, delay builds, and hit margins.
Operations
LivaNova's Operations cover the design, assembly, testing, and validation of medical devices for cardiovascular and neuromodulation use, so manufacturing discipline matters at every step. Quality control is central because device performance, patient safety, and regulatory compliance shape adoption and repeat use. In fiscal 2025, this operational focus supported a business mix built around two core segments and products that must meet strict clinical and regulatory standards.
Outbound Logistics
LivaNova's outbound logistics move finished devices through a regulated channel to hospitals, surgeons, and other clinical customers, so traceability and on-time delivery stay tight. Packaging, labeling, and shipping checks protect sterile product integrity and lower recall risk. In fiscal 2025, this matters because each shipment can affect reported net sales and service levels, especially in high-value neuromodulation and cardiopulmonary products.
Marketing and Sales
LivaNova PLC sells through a clinical, evidence-driven model built around physicians, hospitals, and specialized care centers. Its marketing and sales work leans on product training, clinical support, and strong field ties to turn evidence into procedure-level demand. This matters because the buying decision is often made by care teams, not retail shoppers, so education and peer trust drive adoption. The model helps protect pricing and supports repeat use in complex therapies.
Service
LivaNova's service activity covers post-sale technical support, clinician training, and ongoing help for hospital users. In high-acuity care, fast service matters because device issues can disrupt treatment, so responsive support helps keep systems running and lowers downtime. It also gives LivaNova a direct line to clinical teams, which supports repeat use and longer customer ties.
LivaNova's 2025 model: clinical reliability over volume
LivaNova PLC's primary activities in fiscal 2025 centered on controlled production, regulated distribution, and clinician-led sales for cardiovascular and neuromodulation devices. With about $1.3 billion in net sales in 2025, the value chain stayed tied to quality, traceability, and on-time hospital delivery.
Operations and service mattered most because device safety, training, and post-sale support directly affect procedure success and repeat use. That makes LivaNova PLC's primary chain less about volume and more about reliable clinical performance.
| FY2025 metric | Value |
|---|---|
| Net sales | about $1.3 billion |
Get Your Copy
LivaNova Reference Sources
This is the actual LivaNova Value Chain Analysis document you'll receive upon purchase – no surprises, just the full professional version. The preview below is pulled directly from the complete report, so what you see is exactly what you'll get. Unlock the full, detailed analysis immediately after checkout.
Frequently Asked Questions
It shows a medtech model built around R&D, regulated manufacturing, and clinician support across 2 core fields, cardiovascular and neuromodulation. Its portfolio spans 3 product groups-heart-lung machines, oxygenators, and neuromodulation devices-so value creation depends on engineering depth, evidence generation, and hospital relationships directly.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.